Adpkd Clinical Trials
Here are the 0 most popular medical studies for adpkd
Frequently Asked Questions
Introduction to adpkd
What are the top hospitals conducting adpkd research?
In the realm of medical research, clinical trials play a vital role in advancing our understanding and treatment options for various conditions. One such area of focus is autosomal dominant polycystic kidney disease (ADPKD), a genetic disorder characterized by the growth of numerous cysts in the kidneys. While it may seem that larger institutions dominate the field, several smaller hospitals are making significant contributions to ADPKD research.
One example is Boise Kidney and Hypertension, PLLC located in Nampa, Idaho. Despite having only one active ADPKD trial and one recorded trial overall since 2022, their dedication to pushing boundaries cannot be understated. Similarly, St. Clair Nephrology Research in Roseville, California has also conducted two ADPKD trials but stands out with its first recorded trial dating back to 2020.
Moving over to Mesa, Arizona we find Centricity Research Phoenix Multispecialty making strides in ADPKD research as well. With one ongoing clinical trial and an additional two previously held trials since their inaugural investigation into this condition began in 2019 shows their commitment towards understanding this rare disease better.
MeanwhileCalifornia Institute of Renal Research based La Mesa,, CA makes noteworthy contribution with its recent involvement withinADPKDsphere initiating substantial investigation from year2022.Bridging across state lines,Nevada Kidney DiseaseandHypertension Centers situated at Las Vegas demonstrates equal prowess through conducting similar scale adpkd examinations from year2022.Despite these institutions featuring just single ongoing or previous adpkd experiment experience; they signify crucial stepping-stone towards enriching knowledge pool about this condition
While these hospitals may not have extensive portfolios like some larger counterparts when it comes to ADPKD trials conducted thus far; each study undertaken offers valuable insights into potential treatments and management strategies for individuals affected by this complex disorder.It's incredible how even smaller-scale facilities can contribute significantly to medical advancements, reminding us that progress can be achieved regardless of size or location. Every trial, no matter the scale, plays a part in unraveling the mysteries of ADPKD and offering hope to those impacted by this challenging condition.
Which are the best cities for adpkd clinical trials?
When it comes to ADPKD clinical trials, several cities have emerged as key players in advancing research and treatment. Chicago, Illinois; Jacksonville, Florida; and Rochester, Minnesota each offer two active trials focused on studying promising treatments like RGLS8429 and PB interventions. Additionally, Aurora, Coloradogo, Illinois; Jacksonville, Florida; and Rochester, Minnesota each offer two active trials focused on studying promising treatments like RGLS8429 and PB interventions. Additionally, Aurora, Colorado stands out with two ongoing trials investigating Empagliflozin and daily caloric restriction among other approaches. While Nampa, Idaho contributes with one active trial exploring RGLS8429 alongside other potential breakthroughs. These cities provide individuals living with ADPKD opportunities to participate in cutting-edge clinical trials that may lead to improved outcomes for this condition.
Which are the top treatments for adpkd being explored in clinical trials?
In the realm of clinical trials for autosomal dominant polycystic kidney disease (ADPKD), several treatments are currently under exploration. Among them, RGLS8429, Empagliflozin, and PB each have one active trial dedicated to ADPKD. These novel therapies entered the scene in 2022 with a promise to potentially revolutionize treatment options for this condition. Additionally, daily caloric restriction has also emerged as an intriguing avenue worth investigating further in the context of ADPKD management, with its first listing occurring in 2021. As research progresses and these interventions undergo rigorous evaluation, there is hope that they may pave new paths towards improved outcomes for individuals living with ADPKD.
What are the most recent clinical trials for adpkd?
Exciting advancements are being made in the field of autosomal dominant polycystic kidney disease (ADPKD), with recent clinical trials shedding light on potential treatments. One promising trial investigated the effectiveness of Empagliflozin, a medication commonly used for diabetes treatment, in managing ADPKD progression. Another study focused on RGLS8429, aiming to evaluate its safety and efficacy for patients with ADPKD. Additionally, PB was examined in a Phase 2 trial as a potential therapy option for ADPKD. Although not as recent but still noteworthy is Pravastatin's Phase 4 trial results from August 2017 that provide valuable insights into its use in treating ADPKD. These ongoing efforts hold promise for improving outcomes and quality of life for individuals living with this challenging condition.
What adpkd clinical trials were recently completed?
In October 2017, Kadmon Corporation, LLC completed a clinical trial investigating the use of Tesevatinib in patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD). This trial holds significance for ADPKD research and provides valuable insights into the potential efficacy of Tesevatinib as a treatment option.